The Nasdaq fell hard Wednesday amid a broad stock market decline. Concerns on tariffs, a trade war and inflation still weigh ...

A new AI model can predict the likelihood of premature death from inflammatory bowel disease (IBD) with around 95% accuracy.

Johnson & Johnson JNJ announced that the FDA has granted approval to its key drug, Tremfya, for its second inflammatory bowel disease (IBD) condition — moderately to severely active Crohn’s ...

There is insufficient evidence to support exclusive enteral nutrition as an adjunctive therapy for active ulcerative colitis, despite its good tolerability and low discontinuation rates, according to ...

and BMS has said it remains committed to developing it for IBD. It is hoping that a phase 2 trial in ulcerative colitis called IM011-127, which is using a higher dose of the drug and is due to ...

Compounding pharmacy and IBD 50 newcomer Hims & Hers Health reported ... For the year, Hims expects $2.3 billion to $2.4 billion in sales, above the Street's call for $2.1 billion.

Crohn’s is one of two conditions classified as inflammatory bowel disease (IBD). The other type is ulcerative colitis (UC). Generally, IBD is associated with digestive symptoms. However ...

Almost half of people who died with inflammatory bowel disease (IBD) died prematurely, according to a study published in CMAJ (Canadian Medical Association Journal) that used machine learning models ...

Risk for incident IBD was strongly associated with age over 74 years (hazard ratio [HR], 2.40; 95% CI, 2.12-2.72), but it was also higher in patients aged 65 to 74 years (HR, 2.0; 95% CI, 1.78-2.25), ...

To be included in PREdiCCT, patients must have received the diagnosis of IBD more than 6 months previously, had not change their medication for more than 2 months, and answered “yes” to the ...